A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL (ACCL1033)

Service: Trial Number:
072-12
Principal Investigator: Conducted at:
Orange Coast Memorial
Currently enrolling additional patients:
Yes

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with a five-year survival rate approaching 80%. Several studies have shown highly significant differences in survival among ethnic and racial groups. The outcome for Hispanics has been intermediate between those for Caucasians and African-Americans. The reason(s) for the observed differences in outcome by ethnicity are not clear. We hypothesize that ethnic/racial difference in systemic exposure to 6-MP during maintenance therapy, due primarily to non-adherence to 6-Mercaptopurine (6-MP), could explain the observed differences in outcome of childhood ALL by race/ethnicity. This investigation, as opposed to the standard procedure which are the ways caregivers normally help patients take their medications as directed, will test the feasibility, utility, and efficacy of a technologically sophisticated, web-based medication scheduling and text-messaging reminder system (REM) that prompts directly observed therapy (DOT) of each dose by a parent or designated caregiver, coupled with a multimedia-based interactive patient education program (MIPE), to increase adherence to daily oral 6MP in children with ALL at high risk for non-adherence.

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.
Address
,
 
The email to associate with this registration.